Urgent action is required to equip the pharmaceutical industry with the AI tools, business models, and finance it needs to meet today’s challenges. We set out recommendations to support the acceleration of AI for drug discovery and the reduction of attrition rates, ultimately making more novel drugs available to citizens, in a faster and cheaper way. For both payer and patient, the advantages on offer are reduced cost and time to identify target molecules, which promise to bring new therapeutics to market in a more responsive manner. Read our new report and comment below to ask questions and share your thoughts: Artificial intelligence for drug discovery.